Nanocurcumin Improves Treg Cell Responses in Patients With Mild and Severe Sars-Cov2 Publisher Pubmed



Tahmasebi S¹ ; Saeed BQ² ; Temirgalieva E³ ; Yumashev AV⁴ ; Elesawi MA⁵ ; Navashenaq JG⁶ ; Valizadeh H⁷ ; Sadeghi A⁷ ; Aslani S⁸ ; Yousefi M^{9, 10} ; Jadidiniaragh F¹⁰ ; Adigozalou J¹¹ ; Ahmadi M⁹ ; Roshangar L⁹ Show Affiliations
Source: Life Sciences Published:2021

Abstract

In Coronavirus disease 2019 (COVID-19), a decreased number of regulatory T (Treg) cells and their mediated factors lead to a hyperinflammatory state due to overactivation of the inflammatory cells and factors during the infection. In the current study, we evaluated the Nanocurcumin effects on the Treg cell population and corresponding factors in mild and severe COVID-19 patients. To investigate the Nanocurcumin effects, 80 COVID-19 patients (40 at the severe stage and 40 at the mild stage) were selected and classified into Nanocurcumin and placebo arms. In both the Nanocurcumin and placebo groups, the Treg cell frequency, the gene expression of Treg transcription factor forkhead box P3 (FoxP3), and cytokines (IL-10, IL-35, and TGF-β), as well as the serum levels of cytokines were measured before and after treatment. In both mild and severe COVID-19 patients, Nanocurcumin could considerably upregulate the frequency of Treg cells, the expression levels of FoxP3, IL-10, IL-35, and TGF-β, as well as the serum secretion levels of cytokines in the Nanocurcumin-treated group compared to the placebo group. The abovementioned factors were remarkably increased in the post-treatment with Nanocurcumin before pre-treatment conditions. By contrast, it has been observed no notable alteration in the placebo group. Our findings revealed the SinaCurcumin® effective function in a significant increase in the number of Treg cells and their mediated factors in the Nanocurcumin group than in the placebo group in both mild and severe patients. Hence, it would be an efficient therapeutic agent in rehabilitating COVID-19 infected patients. © 2021 Elsevier Inc.